

Title:
Post-transplant lymphoproliferative disease after liver transplantation

Authors:
José Ignacio Herrero , Carlos Panizo

DOI: 10.17235/reed.2017.5387/2017

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:
Herrero José Ignacio, Panizo Carlos. Post-transplant lymphoproliferative disease after liver transplantation. Rev Esp Enferm Dig 2017. doi: 10.17235/reed.2017.5387/2017.

Enero 2017 • Volumen 109 • Número 1 • Páginas 1-86

CODE: READER ISSN: 100-0108

Revista Española de Enfermedades Digestivas
THE SPANISH JOURNAL OF GASTROENTEROLOGY

Acceso al texto completo en: www.reed.es o www.sped.es

Factor de impacto 100 (P-I): 1.455 (2016)
SCR: 0.34 (2016)

ORGANO OFICIAL DE:
SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA, SOCIEDAD ESPAÑOLA DE ENDOSCOPIA DIGESTIVA Y ASOCIACIÓN ESPAÑOLA DE ECOGRAFÍA DIGESTIVA

SEPO

Editorial Colitis diverticular bleeding. Have we identified the risk factors for massive bleeding yet? J. W. Bercian Valencia	Lesión de Bowdler: diagnóstico por gastroscopia R. Barrio Iglesias, M. N. Barco Irujo, M. Paz Nová y J. E. Domínguez Muñoz	65
Trabajos Originales Risk factors for severity and recurrence of colitis diverticular bleeding N. Anzueto, P. Calvo, A. Arduini, M. Escobar and N. Guzmán	Notas Clínicas	
Management of inflammatory bowel disease: the other diagnosis J. Barrio, A. Aguiló, S. López Quirós, J. Cuervo, M. Acuña-Barca, M. Hernández-Serra, C. García, M. de la Cruz, D. Barrio and A. López-Santesteban	Colitis crónica en adultos: a case report and review of the literature focusing in the prevention of relapsing syndrome M. de Alaveda-Nemón, V. L. Barrio-Cabral and S. L. Latorre	67
Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral therapy A. Barrio, J. Calvo, M. J. López-Alcalá, I. López, M. T. Arce, A. Galván, F. Cañales, E. Fabrega and J. Crespo	Hemangiomas de la pared gástrica. Una localización infrecuente de tumor vascular? I. Alvaró Abad, J. M. García-González, L. Aguirre-Díaz, A. M. Quintana-Rivero y A. Colla-Morero	69
Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease A. A. Cortés, A. Muñoz, Z. Pili, I. Pall and P. Muñoz	Hemólisis por eritropoiesis supresora intravascular C. Pérez-Carpas, A. Escobedo-Sánchez, M. A. Paredes-Capó, J. Arangul-Robich y C. García-Delgado	70
A survey-based analysis of endoscopic quality indicators compliance among Spanish endoscopists I. Fernández-Cruz, F. Argüelles, P. Alonso, J. Salas and S. Soriano	Endoscopia: removal of intubated large variceal gastric: a case report M. Ochoa-García and J. López-Santesteban	73
Revisión Endoscopic resection of colonic polyps in patients on antiplatelet therapy: an evidence-based guideline for clinicians G. Piana, M. Sostero-Salín, C. Salinas, F. Díaz and M. J. Cuervo	Mesenteric schistosomiasis: an unusual cause of abdominal mass A. Tapia-Palacio, M. R. Barrio-Vázquez, J. C. Cordero-Ramos, J. Cordero-Lafont and L. Carballo-Pérez	76
Indicadores en Patología Digestiva Neutrophils of the upper aerodigestive tract: a casea infrecuente de obstrucción intestinal J. Sempere-Jagor, P. Albaladejo-Serra y J. C. García-Pérez	Cartas al Editor	
Neutrophils: a gastric intraluminal A. F. Barrio-Muñoz y R. Barrio-Zelga	Neoplasia neuroendocrina intestinal, un tumor poco habitual M. de Barrio-Nave, J. Barrio-Santesteban y M. N. Barco Rodríguez	79
Neutrophils of the upper aerodigestive tract: a casea infrecuente de obstrucción intestinal C. Ochoa-Salido, C. C. Hernández-Serra, J. Barrio-Santesteban y M. N. Barco Rodríguez	Presentación intestinal de tuberculosis por endoscopia: ¿qué tan asociada a cambios de Biopsias, patología infecciosa y poco conocida? Y. Pineda-Vargas, D. M. Acosta y L. A. Alvaró	80
Endoscopic removal of intubated large variceal gastric A. Pineda, M. N. Barco, J. C. Cordero-Ramos, J. Cordero-Lafont and L. Carballo-Pérez	Parotid endocystic cystadenoma for an adult patient with multiple endocrine neoplasia Y. Sun, H. Zhu and D. Liu	81
All that glitters is not gold. A different cause for an "obscure colitis" A. Pineda, M. N. Barco, J. Cordero-Ramos and L. Carballo-Pérez	Actualización y endoscopia: endoscopia infrecuente de obstrucción intestinal C. Sánchez-Santesteban, L. Guevara-Nieto y J. A. Acosta-Paredes	81
	Perforación múltiple de divertículos de intestino delgado en paciente con síndrome de Ulceras Duodenales R. Barrio-Cabral, A. Barrio-Cabral y E. Muñoz-López	83
	Altoplexia anular como manifestación paraneoplásica de un adenoma actínico gástrico J. Barrio-Santesteban, M. N. Barco-Santesteban y J. de la Fuente-Aguado	83
	Revisores 2016	85

ARAN

www.reed.es

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CE 5387

Post-transplant lymphoproliferative disease after liver transplantation

Jose Ignacio Herrero^{1,2,3} and Carlos Panizo^{2,4}

¹Liver Unit. Clínica Universidad de Navarra. Pamplona, Spain. ²Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona, Spain. ³Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Madrid, Spain. ⁴Hematology Department. Clínica Universidad de Navarra. Pamplona, Spain

ORCID

JIH: 0000-0002-9076-6717

Correspondence: Jose Ignacio Herrero

e-mail: iherrero@unav.es

Key words: Post-transplant lymphoproliferative disease. Non-Hodgkin lymphoma. Liver transplantation. Rituximab.

Dear Editor,

We have read the article “*Post-transplant lymphoproliferative disease in liver transplant recipients*” with great interest. This article reports a series of liver transplant recipients with post-transplant lymphoproliferative disease (PTLD). The effect on patient survival and the potential benefit of rituximab-based therapy are highlighted (1). Rituximab is a chimeric antibody against the CD20 surface marker. This marker is found in most PTLD of a B cell origin (2). A recent study from our center also highlighted the role of rituximab in PTLD therapy (3). The overall response rate of patients treated with rituximab was 66% in both series (1,3). In our series, this included heart, kidney and liver transplant recipients. Rituximab-based therapy was also associated with an increased overall survival. Rituximab should be considered as part of the first-line therapy in patients with PTLD when CD20 expression is present.

References

1. Rubio-Manzanares Dorado M, Álamo Martínez JM, Bernal Bellido C, et al. Síndrome linfoproliferativo en el trasplante hepático. *Rev Esp Enferm Dig* 2017;109:406-13.
2. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. *N Engl J Med* 2012;366:2008-16. DOI: 10.1056/NEJMct1114348
3. Martínez-Calle N, Alfonso A, Rifon J, et al. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: Retrospective, single-center study. *Eur J Hematol* 2016;98:38-43. DOI: 10.1111/ejh.12782